benserazide has been researched along with Huntington Disease in 4 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa has been shown to be a safe pharmacologic agent even after long-term usage." | 2.35 | Levodopa. ( Yahr, MD, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez-Campos, A | 1 |
| Giovannini, P | 1 |
| Cocchi, D | 1 |
| Zanardi, P | 1 |
| Parati, EA | 1 |
| Caraceni, T | 1 |
| Müller, EE | 1 |
| Yahr, MD | 1 |
| Candelise, L | 1 |
| Faglioni, P | 1 |
| Spinnler, H | 1 |
| Vignolo, LA | 1 |
| Rondot, P | 1 |
| Dumas, RJ | 1 |
2 reviews available for benserazide and Huntington Disease
| Article | Year |
|---|---|
Growth hormone secretion in neurological disorders.
Topics: Benserazide; Disease Models, Animal; Dopamine; Growth Hormone; Humans; Huntington Disease; Levodopa; | 1981 |
Levodopa.
Topics: Benserazide; Drug Interactions; Hepatic Encephalopathy; Humans; Huntington Disease; Levodopa; Melano | 1975 |
1 trial available for benserazide and Huntington Disease
| Article | Year |
|---|---|
Letter: Treatment of Huntington's chorea.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Clinical Trials as Topic; Dia | 1973 |
1 other study available for benserazide and Huntington Disease
| Article | Year |
|---|---|
[Dopamine and abnormal movements].
Topics: Benserazide; Body Weight; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Electro | 1972 |